Spero Therapeutics Announces First Patient, First Visit For Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr In Complicated Urinary Tract Infections; Spero Is Entitled To Receive $95M In Development Milestone Payments From GSK Over 2 Years
Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and
